According to experimental data, administration of
interferon in mice before contact with
antigen reduced antibody response, while its presence after
antigen load enhanced them. The aim of this study was to detect possible immunomodulatory effects of unpurified human
alpha-interferon on izohemagglutinin (IZO), and anti-
Forssman antibody (AFA) serum levels during a treatment in patients with
malignant melanoma. Fifty-two patients treated with the same
chemotherapy regimen (ADM-VCR-CPM-
DTIC-PCB) entered the study; 30 received INF 1.000.000 U/24 h x 10 during each cycle, intercycle interval 4 weeks. Twenty-two did not receive
interferon. Initial IZO titers were 1/4-1/256, median 1/64, and for AFA 0-1/14, median 1/7. Following 4 cycles, values for IZO titers were: in the IFN group 1/32-1/262.144, median 1/128; in the non-IFN group range 1/8-1/512, median 1/32. The values for AFA titers were: in the INF group 0-1/442, median between 1/28 and 1/56; in control group 0-1/112, median 1/14. The difference between both median values for the INF group and initial median values was statistically significant. Initial elevation of titers was reversed during a few cycles with both A and B substances and the
Forssman antigen, immunisation of humans is permanent. It would be of interest to ascertain effects of
interferons on antibody response to others
antigens, especially bacterial and viral, during aggressive
chemotherapy. In any case, both experimentally observed phenomena seem to occur in vivo during
interferon treatment of metastatic
melanoma.